Alnylam's in-development RNAi treatment successfully staved off nerve damage related to a rare disease in an ongoing study, the biotech said, early but promising results as the company heads into Phase III with partner Sanofi in tow.
Massachusetts General Hospital investigator Rudy Tanzi has created a new "Alzheimer's-in-a-dish" approach to growing brain cells that he claims provides clear proof of the much-debated amyloid hypothesis as well as a solid target for the disease. And now he reportedly plans to race ahead with his new research process to find a potential megablockbuster drug that can stop the disease in its tracks.
Covance has joined forces with Novartis to develop new ways to help drug developers quickly integrate and analyze huge swaths of study data.
As med tech companies search for innovative ways to improve device implantation and patient outcomes, a new coating technology from Harvard University scientists could reduce blood clotting and bacterial infection associated with commonly used medical devices.
Parexel International is widening its presence in Nottingham, U.K., tapping local grant funds to consolidate some outposts with plans to grow around its latest acquisition.
The list of life science data projects underpinned by Google keeps getting longer. Having signed up to the BRAIN Initiative last week, Google has now teamed up with ISB and SRA International to work on a project for the National Cancer Institute.
Researchers at the University of California, Davis, have solved a century-old mystery by discovering that the bluetongue virus that affects cattle and sheep survives winter by reproducing in midges, which spread the virus.
Novartis has expanded its relationship with the U.K.'s Oxford BioMedica, signing a deal worth up to $90 million that will support the drugmaker's efforts in CAR-T immunotherapies.
Isis Pharmaceuticals has kicked off a Phase III trial on ISIS-SMNrx, a treatment for the rare spinal muscular atrophy, moving forward with the orphan drug as partner Biogen Idec considers whether to take the plunge on the program.
A robotic prosthetic controlled by implanted neuromuscular interfaces has been demonstrated to be clinically successful in a patient for the first time. The researchers expect to treat more patients with novel technology this year. The results are reported in the latest issue of Science Translational Medicine.